Bioweapons: How diseases become weapons

The development of biological weapons is complicated by advancements in biotechnology and the potential misuse of artificial intelligence, which allows for more accurate analysis and modification of pathogens. Experts note that while research can serve legitimate medical or military purposes, the separation between legitimate science and potential abuse remains a significant control problem in modern biotechnology. Biological weapons are defined as the deliberate release of biological substances to harm humans, animals, or plants, typically involving a biological agent and a delivery system. This category includes agents like anthrax and botulinum toxin.
Biological weapons differ from chemical weapons in their mechanism of action: chemical weapons cause immediate toxicity, whereas biological weapons cause infectious diseases that manifest over hours or days. This difference makes predicting the spread of biological threats inherently more difficult due to potential person-to-person transmission.
Internationally, biological weapons are banned under the Biological Weapons Convention (BWC) since 1975, and while chemical weapons are also banned under a separate convention, control over biological weapons lacks comparable international oversight; state control relies heavily on transparency and trust. The dual-use nature of biotechnology means that laboratory equipment used for medical advancements can theoretically be repurposed for military research, complicating detection efforts, as an attack might initially mimic a natural disease outbreak.

* Artificial intelligence could be misused for the development of biological weapons in the future.
* Advances in biotechnology allow for analyzing and modifying pathogens with greater accuracy.
* AI can process large amounts of data more quickly.
* Ken McCallum, head of MI5, warned that artificial intelligence could increase the danger from existing or new biological weapons, even in the hands of non-state actors.
* Anthropic detected and blocked attempts to use AI Claude in connection with potential biological weapons research.
* This included grant applications for Gain-of-Function research and projects investigating avian flu variants more transmissible to mammals.
* Biological weapons consist of a biological agent and a delivery system.
* Known examples of biological agents include anthrax, plague, smallpox, and botulinum toxin.
* The World Health Organization (WHO) and the UN define biological weapons as the deliberate release of such substances to harm humans, animals, or plants.
* Biological weapons are grouped with nuclear and chemical weapons as weapons of mass destruction.
* Chemical weapons cause immediate toxicity; biological weapons cause infectious diseases that can spread from person to person over hours, days, or weeks.
* The Biological Weapons Convention (BWC) entered into force in 1975, prohibiting the development, production, storage, transfer, and use of biological weapons.

The narrative surrounding biological weapons highlights a fundamental tension between scientific capability and international governance. The core challenge lies not just in preventing the release of agents but in managing the inherent dual-use nature of the underlying technology—the same tools used for medical progress are applicable to pathogenic research. This concept exposes the difficulty in establishing effective controls: when legitimate, beneficial research shares infrastructure with potentially harmful research, accountability becomes a fluid problem rather than a fixed legal one.
The distinction drawn between biological and chemical weapons, focusing on the temporal and physical modes of harm (immediate toxicity versus infectious spread), reveals how control systems are structured around specific threat vectors. The current international framework for biological weapons relies on voluntary reporting and trust, which is explicitly noted as lacking a comparable system to that governing chemical weapons, creating a significant vulnerability in verification.
The difficulty in detection stems from the inherent ambiguity of biological events; an intentional release can mimic natural outbreaks, meaning attribution relies heavily on post-event investigation rather than real-time monitoring. This suggests that security and oversight must evolve beyond physical inspection toward establishing deeply integrated, transparent protocols for all related biotechnological research. The historical use of such methods, often shrouded in controversy regarding effectiveness, reinforces the need to scrutinize where control mechanisms are placed—whether at the level of substance prohibition or process regulation.
Bridge Questions: If the challenge is managing dual-use technology, what structural changes are necessary within scientific bodies to embed security and oversight *into* the research process rather than applying external controls after the fact? How can international frameworks evolve to mandate transparency regarding biotechnology research that intersects with potential bioweapon development without violating sensitive proprietary information or impeding legitimate medical advancement? What mechanisms could reliably distinguish between natural biological emergence and deliberate release in complex, rapidly evolving pathogen scenarios?